Vicore Pharma To Move To The Nasdaq Stockholm Mid Cap Segment [Yahoo! Finance]
Nasdaq, Inc. (NDAQ)
Last nasdaq, inc. earnings: 4/22 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nasdaq.com
Company Research
Source: Yahoo! Finance
drugs, angiotensin II type 2 receptor agonists (ATRAGs) today announced that Nasdaq has completed its annual review of its Nordic market capitalization (market cap) segments and will move Vicore Pharma from the Small Cap segment to the Mid Cap segment effective January 2, 2026. Link to press release from Nasdaq. For further information, please contact: Megan Richards, VP of IR and Comms, tel: +1 978 269-4372, megan.richards@vicorepharma.com Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com About Vicore Pharma Holding AB Vicore Pharma Holding AB (publ) is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United S
Show less
Read more
Impact Snapshot
Event Time:
NDAQ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NDAQ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NDAQ alerts
High impacting Nasdaq, Inc. news events
Weekly update
A roundup of the hottest topics
NDAQ
News
- Trump's 5-Day Christmas Break Probably Isn't Coming to Your Office [Yahoo! Finance]Yahoo! Finance
- Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation [Yahoo! Finance]Yahoo! Finance
- Treasury Keeps US Debt Sales Timing After Trump Holiday Move [Yahoo! Finance]Yahoo! Finance
- Nasdaq Halts Magnitude International LtdGlobeNewswire
- Nasdaq Maintains Over a Decade of Listings Leadership in 2025GlobeNewswire
NDAQ
Earnings
- 10/21/25 - Beat
NDAQ
Sec Filings
- 12/15/25 - Form 8-K
- 12/9/25 - Form 4
- 12/9/25 - Form 4
- NDAQ's page on the SEC website